Vimarsana
Biggest News Aggregation in the World

Page 3 - Updated Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Updated Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Updated Phase Today - Breaking & Trending Today

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas - Vimarsana News

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Published: December 12, 2022

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

Source: businessinsider.com
Related Topics:
United StatesMohamed ZakiGenmab DuobodyData From The Observational National Lymphocare StudyAmerican Society Of HematologyLymphoma Research FoundationMacrophage Propertiesj ImmunolNational Institutes Of HealthDrug AdministrationBlood Cancer Press KitExchange CommissionLeukaemia FoundationDevelopment Of Novel AntiEuropean Medicines AgencyAmerican SocietySubcutaneous EpcoritamabRefractory Follicular LymphomaFirst Line TreatmentFollicular LymphomaInitial ResultsRefractory Diffuse Largeb Cell Lymphoma EligibleAutologous Stem Cell TransplantUpdated PhaseYearly ResultsDiffuse Largeb Cell Lymphoma
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas - Vimarsana News

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Published: December 11, 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...

Source: prnewswire.com
Related Topics:
United StatesMohamed ZakiGenmab DuobodyData From The Observational National Lymphocare StudyAmerican Society Of HematologyLymphoma Research FoundationMacrophage Propertiesj ImmunolNational Institutes Of HealthDrug AdministrationBlood Cancer Press KitExchange CommissionLeukaemia FoundationDevelopment Of Novel AntiEuropean Medicines AgencyAmerican SocietySubcutaneous EpcoritamabRefractory Follicular LymphomaFirst Line TreatmentFollicular LymphomaInitial ResultsRefractory Diffuse Largeb Cell Lymphoma EligibleAutologous Stem Cell TransplantUpdated PhaseYearly ResultsDiffuse Largeb Cell Lymphoma
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis - Vimarsana News

Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis

Published: December 5, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

Source: prnewswire.com
Related Topics:
United StatesHong KongUnited KingdomKyongsang BuktoSouth KoreaHaris AliSrdan VerstovsekSelective Inhibitor Of Nuclear ExportSection Leader For Leukemia DivisionMd Anderson Cancer CenterCompany Sponsored Event OnClinical Research For Myeloproliferative NeoplasmsAmerican Society Of HematologyEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportNuclear Transport Inhibition In MyelofibrosisInformation DepartmentKaryopharm Therapeutics IncDavid Geffen School Of MedicineDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionCity Of Hope Comprehensive Cancer CenterKey Opinion LeadersPreview Highlights
SIGMA LITHIUM ACHIEVES OUTSTANDING PROJECT EXPANSION AND FINANCING MILESTONES: INCREASES MINERAL RESERVES BY 63%, TRIPLES NPV TO US$ 15.3 BILLION AND SECURES US$ 100 MILLION DEBT FINANCING - Vimarsana News

SIGMA LITHIUM ACHIEVES OUTSTANDING PROJECT EXPANSION AND FINANCING MILESTONES: INCREASES MINERAL RESERVES BY 63%, TRIPLES NPV TO US$ 15.3 BILLION AND SECURES US$ 100 MILLION DEBT FINANCING

Published: December 4, 2022

INVESTOR VIDEO CONFERENCE CALL December 6, 2022 at 10AM (EST) Registration Link for Zoom video call below: https://us06web.zoom.us/j/83014247697 Zoom Meeting

Source: einnews.com
Related Topics:
United Arab EmiratesMinas GeraisBritish ColumbiaSudhir MaheshwariNoel ObrienMarc Antoine LaporteCalvyn GardnerCabaleiro RodriguezNational InstrumentDubai Financial Services AuthorityBloomberg Short Term Bank Yield IndexLithium Corporation SigmaBattery Grade Sustainable Lithium ConcentrateCirilo ProjectSigma LithiumProduction Expansion StudySynergy CapitalUnited ArabDebt FinancingGrade Sustainable Lithium ConcentrateGreentech Lithium PlantBattery Grade Sustainable LithiumProject ExpansionAna Cabral GardnerCo Chairperson Calvyn Gardner
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the - Vimarsana News

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the

Published: November 3, 2022

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignanciesFour oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) la...

Source: pharmiweb.com
Related Topics:
Al QahirahUnited StatesNew OrleansNew JerseyDavid FreundelEpcoritamab DuobodyEpcoritamab MonotherapyJudith KlimovskyExposition Of The American Society HematologyProduct CommunicationsMacrophage Propertiesj ImmunolErnestn Morial Convention CenterAmerican Society Of HematologyExchange CommissionHealth Care Resource UtilizationDevelopment Of Novel AntiCompany AnnouncementAnnual MeetingAmerican SocietyConvention CenterExecutive Vice PresidentChief Development OfficerYearly ResultsRefractory Diffuse Largeb Cell Lymphoma EligibleAutologous Stem Cell Transplant